I started working at MediChem Life Sciences, a drug discovery and technology company, in a finance role when I graduated from college. deCODE Genetics acquired MediChem three years later, and I stayed on as vice president of finance at the Icelandic company’s U.S. office. Later, I became chief financial officer of Emerald Bio when the company spun out from deCODE in 2009…Read More

With over a decade of industry expertise, I have been at the forefront of numerous, successful structure determination research collaborations, including hepatitis C virus (HCV), oncology and diabetes targets. Prior to joining Beryllium, I was a crystallographer and senior research scientist at the Seattle Structural Genomics Center for Infectious Disease (SSGCID)…Read More

I began my career in the biotech industry in 1995 and it has included positions at Thermo Fisher and Lonza Biologics. I earned my Bachelor’s degree from Old Dominion University. As a Navy spouse I had the opportunity to live all over the world from Italy to Hawaii to Washington State…Read More

I bring to Beryllium over a decade of research experience in phenotypic profiling, especially in neurobiology. As an entrepreneurial scientist, I am accomplished in the fields of neuroscience, stem cell biology, and drug discovery. The challenge that I hope to address is creating innovation and improved efficiency in drug discovery…Read More

I have been working with an interdisciplinary team to build and strengthen fragment-based discovery at Beryllium for ten years. I worked as the project lead on the effort to build our first in-house fragment screening collection, the metabolome-influenced “Fragments of Life.” …Read More